Literature DB >> 29412812

Intestinal peptide changes after bariatric and minimally invasive surgery: Relation to diabetes remission.

Lidia Castagneto Gissey1, James Casella Mariolo1, Geltrude Mingrone2.   

Abstract

Bariatric surgery is very effective in achieving and maintaining weight loss but it is also associated with improvement of obesity metabolic complications, primarily type 2 diabetes (T2D). Remission of T2D or at least a net improvement of glycemic control persists for at least 5 years. The bypass of duodenum and of the first portion of the jejunum up to the Treitz ligament as in Roux-en-Y Gastric Bypass (RYGB), or the bypass of the duodenum, the entire jejunum and the first tract of the ileum, such as in Bilio-Pancreatic Diversion (BPD), achieve different results on insulin sensitivity. Insulin resistance is the major driver of T2D manifesting long before insulin secretion failure. In fact, T2D development can be prevented by treatment with insulin sensitizing agents. Interestingly, RYGB improves hepatic insulin sensitivity while BPD ameliorates whole-body insulin sensitivity. Two major theories have been advocated to explain the early remission of T2D following RYGB or BPD before a meaningful weight loss takes place, the foregut and the hindgut hypotheses. The former holds that the bypass of the proximal intestine, i.e. duodenum and jejunum, prevents the secretion of signals - including nervous transmitters and hormones - promoting insulin resistance, the latter instead states that the delivery of nutrients directly into the ileum stimulates the secretion of hormones improving glucose disposal. The most studied candidate is Glucagon Like Peptide 1 (GLP1). However, while there is unambiguous evidence that GLP-1 stimulates insulin secretion, its direct action in lowering insulin resistance, independently of the effect on weight loss secondary to its satiety action, is utterly controversial. In this review we examine the effects on T2D and gastrointestinal peptide secretion produced by different types of metabolic surgery and by minimally invasive endoscopic surgery, whose utilization for the treatment of obesity and T2D is gaining wider interest and acceptance.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Bariatric surgery; Intestinal peptides; Metabolic surgery; Minimally invasive endoscopic surgery; Obesity; Type 2 diabetes

Mesh:

Substances:

Year:  2018        PMID: 29412812     DOI: 10.1016/j.peptides.2017.12.010

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  6 in total

Review 1.  Impact of bariatric surgery on type 2 diabetes: contribution of inflammation and gut microbiome?

Authors:  Jean Debédat; Chloé Amouyal; Judith Aron-Wisnewsky; Karine Clément
Journal:  Semin Immunopathol       Date:  2019-04-25       Impact factor: 9.623

2.  Comparing the Anti-diabetic Effect of Sleeve Gastrectomy with Transit Bipartition Against Sleeve Gastrectomy and Roux-en-Y Gastric Bypass Using a Diabetic Rodent Model.

Authors:  Pengpeng Liu; Jason Widjaja; Ponnie Robertlee Dolo; Libin Yao; Jian Hong; Yong Shao; Xiaocheng Zhu
Journal:  Obes Surg       Date:  2021-01-28       Impact factor: 4.129

Review 3.  The Role of Beta Cell Recovery in Type 2 Diabetes Remission.

Authors:  Mara Suleiman; Lorella Marselli; Miriam Cnop; Decio L Eizirik; Carmela De Luca; Francesca R Femia; Marta Tesi; Silvia Del Guerra; Piero Marchetti
Journal:  Int J Mol Sci       Date:  2022-07-04       Impact factor: 6.208

Review 4.  Bariatric/Metabolic Surgery.

Authors:  Lidia Castagneto-Gissey; James Casella-Mariolo; Geltrude Mingrone
Journal:  Handb Exp Pharmacol       Date:  2022

Review 5.  Obesity Surgery and Cancer: What Are the Unanswered Questions?

Authors:  Lidia Castagneto-Gissey; James Casella-Mariolo; Giovanni Casella; Geltrude Mingrone
Journal:  Front Endocrinol (Lausanne)       Date:  2020-04-15       Impact factor: 5.555

6.  Modulation of Food Intake by Differential TAS2R Stimulation in Rat.

Authors:  Carme Grau-Bové; Alba Miguéns-Gómez; Carlos González-Quilen; José-Antonio Fernández-López; Xavier Remesar; Cristina Torres-Fuentes; Javier Ávila-Román; Esther Rodríguez-Gallego; Raúl Beltrán-Debón; M Teresa Blay; Ximena Terra; Anna Ardévol; Montserrat Pinent
Journal:  Nutrients       Date:  2020-12-10       Impact factor: 5.717

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.